Your browser doesn't support javascript.
loading
A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity.
Han, Dong; Xu, Yinfeng; Zhao, Xinping; Mao, Yunyun; Kang, Qinglin; Wen, Weihong; Yu, Xiaoyan; Xu, Lei; Liu, Fujia; Zhang, Mengyao; Cui, Jiazhen; Wang, Zhang; Yang, Zhixin; Du, Peng; Qin, Weijun.
Afiliação
  • Han D; Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Xu Y; Beijing Institute of Biotechnology, Beijing, China.
  • Zhao X; Beijing Institute of Biotechnology, Beijing, China; PLA Center for Disease Control and Prevention, Beijing, China.
  • Mao Y; Beijing Institute of Biotechnology, Beijing, China.
  • Kang Q; Beijing Institute of Biotechnology, Beijing, China.
  • Wen W; Institute of Medical Research, Northwestern Polytechnical University, Xi'an, China.
  • Yu X; Beijing Institute of Biotechnology, Beijing, China.
  • Xu L; Beijing Institute of Biotechnology, Beijing, China.
  • Liu F; Beijing Institute of Biotechnology, Beijing, China.
  • Zhang M; Beijing Institute of Biotechnology, Beijing, China.
  • Cui J; Beijing Institute of Biotechnology, Beijing, China.
  • Wang Z; Beijing Institute of Biotechnology, Beijing, China; Hainan Medical University, Haikou, China.
  • Yang Z; Beijing Institute of Biotechnology, Beijing, China. Electronic address: yy_xiao@126.com.
  • Du P; Beijing Institute of Biotechnology, Beijing, China. Electronic address: dudedu@sina.com.
  • Qin W; Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Electronic address: qinwj@fmmu.edu.cn.
Biochem Biophys Res Commun ; 534: 134-140, 2021 01 01.
Article em En | MEDLINE | ID: mdl-33341068
TIGIT is an emerging novel checkpoint target that is expressed on both tumor-infiltrating T cells and NK cells. Some current investigational antibodies targeting TIGIT have also achieved dramatic antitumor efficacy in late clinical research. Most recently, the relevance of NK cell-associated TIGIT signaling pathway to tumors' evasion of the immune system has been clearly revealed, which endows NK cells with a pivotal role in the therapeutic effects of TIGIT blockade. In this article, we describe a novel anti-TIGIT monoclonal antibody, AET2010, which was acquired from a phage-displayed human single-chain antibody library through a cell panning strategy. With emphasis on its regulation of NK cells, we confirmed the excellent ex vivo and in vivo antitumor immunity of AET2010 mediated by the NK-92MI cells. Intriguingly, our work also revealed that AET2010 displays a lower affinity but parallel avidity and activity relative to MK7684, an investigational monoclonal antibody from MSD, implying a reasonable balance of potency and potential side effects for AET2010. Together, these results are promising and warrant further development of AET2010.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Receptores Imunológicos / Anticorpos Monoclonais / Neoplasias Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Receptores Imunológicos / Anticorpos Monoclonais / Neoplasias Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article